TMCnet News
Mitobridge Presents Preclinical Data Demonstrating Beneficial Effects of PPARd Modulators in Acute Kidney Injury at American Society of Nephrology Annual MeetingMitobridge, Inc., dedicated to the discovery and development of therapeutics that improve mitochondrial function, presented results highlighting the potential of selective PPARd modulation to treat acute kidney injury (AKI). AKI is the sudden loss of kidney function that often occurs in hospitalized patients following cardiac and/or vascular surgery, trauma, infection, cardiac disease or treatment with nephrotoxic anti-cancer therapy. The data, presented last week at the Annual Meeting of the American Society of Nephrology (ASN), demonstrated that Mitobridge's proprietary compound MA-0217 (also known as MTB-2) corrects the mitochondrial deficits and alleviates the renal dysfunction in a rat ischemia reperfusion AKI (IR-AKI) model. Additionally, MA-0204, a close analog of MA-0217, dosed post IR-AKI in a rat model of patients with hypertension, chronic kidney disease and diabetes and thereby at high risk to develop AKI, reduced kidney injury, accelerated recovery of kidney function and decreased the onset of fibrosis and slowed progression of diabetes and chronic kidney disease by 4 weeks. The posters are available on the Company's website: http://www.mitobridge.com/news/publications. "These proof-of-concept data demonstrated that MA-0217 can enhance mitochondrial fatty acid oxidation in human kidney cells and restore kidney function in animal models of the disease," commented Effie Tozzo, Senior Vice President, Translational Sciences at Mitobridge. "These results are encouraging and support advancing MA-0217 into clinical development as a first-in-class interventional approach for cardiac surgery-associated acute kidney injury (CSA-AKI)." "AKI is a serious condition and there are no currently approved therapies to help manage patients," said Bruce A. Molitoris, Professor of Medicine and Director of the Indiana Center for Biological Microscopy at Indiana University (News - Alert). "MA-0217 may address the cellular injury, mitochondrial dysfunction and organ damage associated with AKI and represents an innovative option for this life-threatening condition. The presented data are quite promising and I look forward to seeing the compound enter clinical development."
About Mitobridge
About MA-0217
About AKI
View source version on businesswire.com: http://www.businesswire.com/news/home/20171106005791/en/ |